Cytokine cascades in acute graft-versus-host disease

Transplantation

Volumn 64, Issue 4, 1997, Pages 553-558

  Krenger, Werner ^a,b   Hill, Geoffrey R ^a   Ferrara, James L M ^a,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 2; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL TISSUE; BONE MARROW TRANSPLANTATION; GRAFT VERSUS HOST REACTION; HOST RESISTANCE; HOST SUSCEPTIBILITY; IMMUNOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; MOUSE; NONHUMAN; OUTCOMES RESEARCH; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE ACTIVATION;

ACUTE DISEASE; CYTOKINES; GRAFT VS HOST DISEASE; HUMANS;

EID: 0030960998     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199708270-00001     Document Type: Review

References (69)

1. Storb R. Prevention of graft-versus-host disease after bone marrow transplantation. Transplant Proc 1995; 27: 2653.
2. Ringden O, Deeg HJ. Clinical spectrum of graft-versus-host disease. In: Ferrara JLM, Deeg HJ, Burakoff SJ, eds. Graft-vs-host disease, 2nd ed. New York: M. Dekker, Inc., 1997: 525.
3. Hakim FT, Mackall CL. The immune system: effector and target of graft-versus-host disease. In: Ferrara JLM, Deeg HJ, Burakoff SJ, eds. Graft-vs-host disease. New York: M. Dekker, Inc., 1997: 257.
4. Martin PJ, Kernan NA. T-cell depletion for GVHD prevention in humans. In: Ferrara JLM, Deeg HJ, Burakoff SJ, eds. Graft-vs-host disease, 2nd ed. New York: M. Dekker, Inc., 1997: 615.
5. Holler E, Ferrara JLM. Antagonists of inflammatory cytokines: prophylactic and therapeutic applications. In: Ferrara JLM, Deeg HJ, Burakoff SJ, eds. Graft-vs-host disease. New York: M. Dekker, Inc., 1997: 667.
6. Xun CQ, Thompson JS, Jennings CD, et al. Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2-incompatible transplanted SCID mice. Blood 1994; 83: 2360.
7. Remberger M, Ringden O, Markling L. TNFα levels are increased during bone marrow transplantation conditioning in patients who develop acute GVHD. Bone Marrow Transplant 1995; 15: 99.
8. Eissner G, Kohlhuber F, Grell M, et al. Critical involvement of transmembrane tumor necrosis factor-alpha in endothelial programmed cell death mediated by ionizing radiation and bacterial endotoxin. Blood 1995; 86: 4184.
9. Behrends U, Peter RU, Hintermeier-Knabe R, et al. Ionizing radiation induces human intercellular adhesion molecule-1 in vitro. J Invest Dermatol 1994; 103: 726.
10. Lichtman A, Krenger W, Ferrara JLM. Cytokine networks. In: Ferrara JLM, Deeg HJ, Burakoff SJ, eds. Graft-vs-host disease, 2nd ed. New York: M. Dekker, Inc., 1997: 179.
11. Nestel FP, Price KS, Seemayer TA, et al. Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor alpha during graft-versus-host disease. J Exp Med 1992; 175: 405.
12. Holler E, Kolb HJ, Moller A, et al. Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood 1990; 75: 1011.
13. Holler E, Kolb HJ, Mittermueller J, et al. Modulation of acute graft-versus-host disease after allogeneic bone marrow transplantation by tumor necrosis factor a (TNFa) release in the course of pretransplant conditioning: role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNFa (MAK 195F). Blood 1995; 86: 890.
14. Korngold R, Sprent J. T cell subsets in graft-vs.-host disease. In: Burakoff SJ, Deeg HJ, Ferrara J, Atkinson K, eds. Graft-vs.-host disease: immunology, pathophysiology, and treatment. New York: M. Dekker, Inc., 1990: 31.
15. Korngold R, Sprent J. Features of T cells causing H-2 restricted lethal graft-vs-host disease across minor histocompatibility barriers. J Exp Med 1982; 155: 872.
16. Mosmann TR, Cherwinski H, Bond MW, et al. Two types of murine helper T cell clone: I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986; 136: 2348.
17. Seder RA. The functional role of CD8+ T helper type 2 cells. J Exp Med 1995; 181: 5.
18. Via CS, Finkelman FD. Critical role of interleukin-2 in the development of acute graft-versus-host disease. Int Immunol 1993; 5: 565.
19. Theobald M, Nierle T, Bunjes D, et al. Host-specific interleukin-2-secreting donor T-cell precursors as predictors of acute graft-versus-host disease in bone marrow transplantation between HLA-identical siblings. N Engl J Med 1992; 327: 1613.
20. Schwarer AP, Jiang YZ, Brookes PA, et al. Frequency of anti-recipient alloreactive helper T-cell precursors in donor blood and graft-versus-host disease after HLA-identical sibling bone-marrow transplantation. Lancet 1993; 341: 203.
21. Miyamoto T, Akashi K, Hayashi S, et al. Serum concentration of the soluble interleukin-2 receptor for monitoring acute graft-versus-host disease. Bone Marrow Transplant 1996; 17: 185.
22. Ringden O. Cyclosporine in allogeneic bone marrow transplantation. Transplantation 1986; 42: 445.
23. Lazarus HM, Volgelsang GB, Rowe JM. Prevention and treatment of acute graft versus host disease: the old and the new. A report from the Eastern Cooperative Oncology Group (ECOG). Bone Marrow Transplant 1997; 19: 577.
24. Massumoto C, Benyunes MC, Sale G. Close stimulation of aucte graft-versus-host disease by interleukin-2 administered after autologous bone marrow transplantation for hematologic malignancy. Bone Marrow Transplant 1996; 17: 351.
25. Soiffer RJ, Murray C, Cochran K, et al. Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depeleted bone marrow transplantation. Blood 1992; 79: 517.
26. Robinson N, Sanders JE, Benyunes MC, et al. Phase I trial of interleukin-2 after unmodified HLA-matched sibling bone marrow transplantation for children with acute leukemia. Blood 1996; 87: 1249.
27. Sykes M, Romick ML, Hoyles KA, et al. In vivo administration of interleukin 2 plus T cell-depleted syngeneic marrow prevents graft-versus-host disease mortality and permits alloengraftment. J Exp Med 1990; 171: 645.
28. Szebeni J, Wang MG, Pearson DA, et al. IL-2 inhibits early increases in serum gamma interferon levels associated with graft-versus-host disease. Transplantation 1994; 58: 1385.
29. Sykes M, Abraham VS, Harty MW, et al. IL-2 reduces graft-versus-host disease and preserves a graft-versus-leukemia effect by selectively inhibiting CD4+ T cell activity. J Immunol 1993; 150: 197.
30. Wang MG, Szebeni J, Pearson DA, et al. Inhibition of graft-versus-host disease by interleukin-2 treatment is associated with altered cytokine production by expanded graft-versus-host-reactive CD4+ helper cells. Transplantation 1995; 60: 481.
31. Troutt AB, Maraskovsky E, Rogers LA, et al. Quantitative analysis of lymphokine expression in vivo and in vitro. Immunol Cell Biol 1992; 70: 51.
32. Allen RD, Staley TA, Sidman CL. Differential cytokine expression in acute and chronic murine graft-versus-host disease. Eur J Immunol 1993; 23: 333.
33. Ferrara JLM, Cooke KR, Pan L, et al. The immunopathophysiology of acute graft-versus-host disease. Stem Cells 1996; 14: 473.
34. Mowat A. Antibodies to IFN-gamma prevent immunological mediated intestinal damage in murine graft-versus-host reactions. Immunology 1989; 68: 18.
35. Dickinson AM, Sviland L, Dunn J, et al. Demonstration of direct involvement of cytokines in graft-versus-host reactions using an in vitro skin explant model. Bone Marrow Transplant 1991; 7: 209.
36. Huchet R, Bruley-Rosset M, Mathiot C, et al. Involvement of IFN-gamma and transforming growth factor-beta in graft-vs-host reaction-associated immunosuppression. J Immunol 1993; 150: 2517.
37. Krenger W, Falzarano G, Delmonte J, et al. Interferon-γ suppresses T-cell proliferation to mitogen via the nitric oxide pathway during experimental acute graft-versus-host disease. Blood 1996; 88: 1113.
38. Rus V, Svetic A, Nguyen P, et al. Kinetics of Th1 and Th2 cytokine production during the early course of acute and chronic murine graft-versus-host disease. J Immunol 1995; 155: 2396.
39. Brok HPM, Heidt PJ, van der Meide PH, et al. Interferon-γ prevents graft-versus-host disease after allogeneic bone marrow transplantation in mice. J Immunol 1993; 151: 6451.
40. Krenger W, Snyder KM, Byon CH, et al. Polarized type 2 alloreactive CD4+ and CD8+ donor T cells fail to induce experimental acute graft-versus-host disease. J Immunol 1995; 155: 585.
41. Fowler DH, Kurasawa K, Husebekk A, et al. Cells of the Th2 cytokine phenotype prevent LPS-induced lethality during murine graft-versus-host reaction. J Immunol 1994; 152: 1004.
42. Niederwieser D, Herold M, Woloszczuk W, et al. Endogenous IFN-gamma during human bone marrow transplantation. Transplantation 1990; 50: 620.
43. Kennedy MJ, Vogelsang GB, Jones RJ, et al. Phase I trial of interferon gamma to potentiate cyclosporine-induced graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer. J Clin Oncol 1994; 12: 249.
44. Dickinson AM, Sviland L, Hamilton PJ, et al. Cytokine involvement in predicting clinical graft-versus-host disease in allogeneic bone marrow transplant recipients. Bone Marrow Transplant 1994; 13: 65.
45. Tanaka J, Imamura M, Kasai M, et al. Cytokine gene expression in the mixed lymphocyte culture in allogenic bone marrow transplants as a predictive method for transplantation-related complications. Br J Haematol 1994; 87: 415.
46. Roncarolo MG, Bigler M, Ciuti E, et al. Immune responses by cord blood cells. Blood Cells 1994; 20: 573.
47. Kurtzberg J, Laughlin M, Graham ML. Placental blood as a source of hematopoietic stem cells for transplantation into un-related recipients. N Engl J Med 1996; 335: 157.
48. Heinzel FP, Sadick MD, Holaday BJ, et al. Reciprocal expression of interferon-γ or interleukin-4 during the resolution or progression of murine leishmaniasis. J Exp Med 1989; 169: 59.
49. Romagnani S. Lymphokine production by human T cells in disease states. Annu Rev Immunol 1994; 12: 227.
50. DeWit D, Van Mechelen M, Zanin C, et al. Preferential activation of Th2 cells in chronic graft-versus-host disease. J Immunol 1993; 150: 361.
51. Via CS, Rus V, Gately MK, et al. IL-12 stimulates the development of acute graft-versus-host disease in mice that would normally develop chronic, autoimmune graft-versus-host disease. J Immunol 1994; 153: 4040.
52. Krenger W, Ferrara JLM. Graft-versus-host disease and the Th1/Th2 paradigm. Immunol Res 1996; 15: 50.
53. Strom TB, Roy-Chaudhury P, Manfro R, et al. The Thi/Th2 paradigm and the allograft response. Curr Opin Immunol 1996; 8: 688.
54. Piccotti JR, Chan SY, Goodman RE. IL-12 antagonism induces T helper 2 responses yet exacerbates cardiac allograft rejection. J Immunol 1996; 157: 1951.
55. Krenger W, Cooke KR, Sonis ST, et al. Transplantation of polarized type 2 donor T cells reduces mortality caused by experimental eraft-versus-host disease. Transplantation 1996; 62: 1278.
56. Krenger W, Snyder K, Smith S, et al. Effects of exogenous interleukin-10 in a murine model of graft-versus-host disease to minor histocompatibility antigens. Transplantation 1994; 58: 1251.
57. Atkinson K, Matias C, Guiffre A, et al. In vivo administration of granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage CSF, interleukin-1 (IL-1), and IL-4, alone and in combination, after allogeneic murine hematopoietic stem cell transplantation. Blood 1991; 77: 1376.
58. Fowler DH, Gress RE. Graft-versus-host disease as a Th1-type process: regulation by donor cells of Th2 cytokine phenotype. In: Ferrara JLM, Deeg HJ, Burakoff SJ, eds. Graft-vs.-host disease. New York: M. Dekker, Inc., 1997: 479.
59. Bensinger WI, Clift RA, Anasetti C, et al. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony stimulating factor. Stem Cells 1996; 14: 90.
60. Pan L, Delmonte J, Jalonen CK, et al. Pretreatment of donors with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type 2 cytokine production and reduces severity of experimental graft versus host disease. Blood 1995; 86: 4422.
61. Braun YM, Lowin B, French L, et al. Cytotoxic T cells deficient in both functional Fas ligand and perform show residual cytolytic activity yet lose their capacity to induce lethal acute graft-versus-host disease. J Exp Med 1996; 183: 657.
62. Baker MB, Altman NH, Podack ER, et al. The role of cell-mediated cytotoxicity in acute GVHD after MHC-matched allogeneic bone marrow transplantation in mice. J Exp Med 1996; 183: 2645.
63. Ferrara J, Guillen FJ, Sleckman B, et al. Cutaneous acute graft-versus-host disease to minor histocompatibihty antigens in a murine model: histologic analysis and correlation to clinical disease. J Invest Dermatol 1986; 86: 371.
64. Hoffman RA, Langrehr JM, Simmons RL. Induction of nitric oxide synthesis during the immune response. In: Ildstad ST, ed. Chimerism and tolerance. Austin, TX: R.G. Landes Co., 1995: 79.
65. McCarthy PL, Abhyankar S, Neben S, et al. Inhibition of interleukin-1 by an interleukin-1 receptor antagonist prevents graft-versus-host disease. Blood 1991; 78: 1915.
66. Abhyankar S, Gilliland DG, Ferrara JLM. Interleukin 1 is a critical effector molecule during cytokine dysregulation in graft-versus-host disease to minor histocompatibility antigens. Transplantation 1993; 56: 1518.
67. Piguet PF, Grau GE, Allet B, et al. Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-versus-host disease. J Exp Med 1987; 166: 1280.
68. Falzarano G, Krenger W, Snyder KM, et al. Suppression of B cell proliferation to lipopolysaccharide is mediated through induction of the nitric oxide pathway by tumor necrosis factor-α in mice with acute graft-versus-host disease. Blood 1996; 87: 2853.
69. Steinshamn S, Bemelmans MH, Buurman WA, et al. Granulocytopenia reduces release of soluble TNF receptor p75 in endotoxin-stimulated mice: a possible mechanism of enhanced TNF activity. Cytokine 1995; 7: 50.